TITLE

New insights into the biology of multiple myeloma using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level

AUTHOR(S)
Nickenig, C.; Lang, N. K.; Schoch, C.; Hiddemann, W.; Haferlach, T.
PUB. DATE
November 2001
SOURCE
Annals of Hematology;Nov2001, Vol. 80 Issue 11, p662
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Up to now only limited information is available about the significance of chromosomal aberrations in multiple myeloma (MM) and about the time point of the neoplastic transformation. Fluorescence in situ hybridization (FISH) combined with standard May-Grünwald-Giemsa (MGG) staining or immunophenotyping on a single cell level were applied. Bone marrow (BM) samples were obtained from 11 patients with morphologically proven multiple myeloma. For detection of the chromosomal aberrations, we used FISH on interphase nuclei with commercially available centromere-specific probes for chromosomes 1, 7, 9, 11, 15, and 17 and further DNA probes for 5p13, 5q31, Rb-gene (13q14), cyclin D1 gene (11q13), and p53 gene (17p13). The aberration rate differed between 14% and 71% on bone marrow smears. Using the combination of MGG and FISH we analyzed eight patients. A total of 2622 bone marrow cells were morphologically identified and investigated for their specific chromosomal aberrations. For all probes applied, 57 cells of the erythropoietic lineage, 698 cells of the granulopoietic lineage, and 168 lymphocytes showed two normal FISH signals. Of 1723 nuclei of plasma cells, 464 (26.9%) were also not aberrant, whereas all other nuclei of plasma cells (n=1259, 73%) showed a specific aberration. Combination of fluorescence immunophenotyping and in situ hybridization (FICTION) was applied in 10 of 11 patients. Seventy-eight investigated CD34-positive precursor cells did not show any specific aberration detected before in the plasma cell compartment. In conclusion, the combination of MGG and FISH on a single cell level demonstrated that only plasma cells bore the chromosomal aberration and MM did not evolve at an early cell level.
ACCESSION #
15684809

 

Related Articles

  • Classify Hyperdiploidy Status of Multiple Myeloma Patients Using Gene Expression Profiles. Li, Yingxiang; Wang, Xujun; Zheng, Haiyang; Wang, Chengyang; Minvielle, Stéphane; Magrangeas, Florence; Avet-Loiseau, Hervé; Shah, Parantu K.; Zhang, Yong; Munshi, Nikhil C.; Li, Cheng // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Multiple myeloma (MM) is a cancer of antibody-making plasma cells. It frequently harbors alterations in DNA and chromosome copy numbers, and can be divided into two major subtypes, hyperdiploid (HMM) and non-hyperdiploid multiple myeloma (NHMM). The two subtypes have different survival...

  • Cytogenetics of Multiple Myeloma. Trčić, Ružica Lasan; Skelin, Ika Kardum; Šušterčić, Dunja; Planinc-Peraica, Ana; Ajduković, Radmila; Hariš, Višnja; Kušec, Rajko; Begović, Davor // Collegium Antropologicum;Mar2010, Vol. 34 Issue 1, p41 

    Great studies of multiple myeloma (MM) strongly suggested that specific chromosomal changes are of prognostic significance in patients with MM¹. We have performed cytogenetic analysis and recently fluorescent in situ hybridization (FISH) on 43 cases of MM. Clonal chromosomal changes were...

  • Plasma Cell Specific Fluorescence in situ Hybridisation for Multiple Myeloma. Talley, Polly; Watmore, A. // Journal of Medical Genetics;Sep2003 Supplement, Vol. 40, pS56 

    Multiple Myeloma (MM) is a neoplastic proliferation of bone marrow plasma cells. Plasma cells, even in MM, can be present in relatively low numbers and divide infrequently. Consequently, conventional metaphase cytogenetic studies can be extremely difficult. Chromosome abnormalities are reported...

  • Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Chiecchio, L.; Protheroe, R. K. M.; Ibrahim, A. H.; Cheung, K. L.; Rudduck, C.; Dagrada, G. P.; Cabanas, E. D.; Parker, T.; Nightingale, M.; Wechalekar, A.; Orchard, K. H.; Harrison, C. J.; Cross, N. C. P.; Morgan, G. J.; Ross, F. M. // Leukemia (08876924);Sep2006, Vol. 20 Issue 9, p1610 

    In myeloma, the prognostic impact of different strategies used to detect chromosome 13 deletion (Δ13) remains controversial. To address this, we compared conventional cytogenetics and interphase fluorescence in situ hybridization (iFISH) in a large multicenter study (n=794). The ability to...

  • Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma. Gao, Xiao; Li, Chunming; Zhang, Run; Yang, Ruifang; Qu, Xiaoyan; Qiu, Hairong; Xu, Jiaren; Lu, Hua; Li, Jianyong; Chen, Lijuan // Medical Oncology;Sep2012, Vol. 29 Issue 3, p2200 

    Conventional cytogenetic analysis is often hampered owing to the low mitotic index of multiple myeloma (MM) cells in bone marrow samples of MM. Interphase fluorescence in situ hybridization (I-FISH) analysis combined with magnetic-activated cell sorting (MACS) has substantially enhanced the...

  • Split hand/foot malformation due to chromosome 7q aberrations(SHFM1): additional support for functional haploinsufficiency as the causative mechanism. van Silfhout, Anneke T.; van den Akker, Peter C.; Dijkhuizen, Trijnie; Verheij, Joke B. G. M.; Olderode-Berends, Maran J. W.; Kok, Klaas; Sikkema-Raddatz, Birgit; van Ravenswaaij-Arts, Conny M. A. // European Journal of Human Genetics;Nov2009, Vol. 17 Issue 11, p1432 

    We report on three patients with split hand/foot malformation type 1 (SHFM1). We detected a deletion in two patients and an inversion in the third, all involving chromosome 7q21q22. We performed conventional chromosomal analysis, array comparative genomic hybridization and fluorescence in situ...

  • Detection of Genomic Abnormalities in Multiple Myeloma. Hartmann, Luise; Biggerstaff, Julie Sanford; Chapman, Douglas B.; Scott, Janice M.; Johnson, Krystal R.; Ghirardelli, Keely M.; Fritschle, Wayne K.; Martinez, Dolores L.; Bennington, Richard K.; de Baca, Monica E.; Wells, Denise A.; Loken, Michael R.; Zehentner, Barbara K. // American Journal of Clinical Pathology;Nov2011, Vol. 136 Issue 5, p712 

    Multiple myeloma (MM) is a hematopoietic neoplasm characterized by malignant plasma cells (PCs) that accumulate in the bone marrow. A number of different genomic abnormalities are associated with MM; however, detection of these by fluorescence in situ hybridization (FISH) can be limited by the...

  • Prognostic factors in multiple myeloma: practicability for clinical practice and future perspectives. Haferlach, T.; Löffler, H. // Leukemia (08876924);Dec97 Supplement 5, Vol. 11, pS5 

    Clinical staging systems for multiple myeloma published so far have not always been reliable in predicting a prognosis and do not provide important insights into the biology of the disease. Therefore, new single independent factors or their combination are needed in order to define prognostic...

  • International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Fonseca, R.; Bergsagel, P. L.; Drach, J.; Shaughnessy, J.; Gutierrez, N.; Stewart, A. K.; Morgan, G.; Van Ness, B.; Chesi, M.; Minvielle, S.; Neri, A.; Barlogie, B.; Kuehl, W. M.; Liebisch, P.; Davies, F.; Chen-Kiang, S.; Durie, B. G. M.; Carrasco, R.; Sezer, Orhan; Reiman, Tony // Leukemia (08876924);Dec2009, Vol. 23 Issue 12, p2210 

    Myeloma is a malignant proliferation of monoclonal plasma cells. Although morphologically similar, several subtypes of the disease have been identified at the genetic and molecular level. These genetic subtypes are associated with unique clinicopathological features and dissimilar outcome. At...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics